The Innovative Medicines Initiative (IMI) is the result of a partnership between the European Union (EU), represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its purpose is to allow better cooperation between industry in a field and scientists. The research carried out within IMI must be precompetitive, with an important training component. The initiative responds, in particular, to safety and efficiency issues.
IMI2 launches its call for projects 2020, whose themes 4 and 5 relate specifically to cancer. Applications for this call for projects take place in 2 stages.
Submission deadline step 1: April 21, 2020 at 5 p.m. (Brussels time)
Submission deadline step 2: November 5, 2020
Consult the text of the PAA.
Apply here (theme 4 – Tumor plasticity) or here (theme 5 – Proton versus photon therapy for oesophageal cancer – a trimodality strategy).
